
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly has demonstrated substantial growth in its top-line revenue and operational efficiencies, supported by a capable leadership team navigating the company’s strategic initiatives. The company’s robust pipeline, featuring promising developments such as orforglipron, retatrutide, and donanemab, showcases significant potential for further revenue expansion and market penetration, particularly in light of favorable trial results and regulatory support. Revenue projections for 2024, 2025, and 2026 have been positively adjusted to $42.6 billion, $51.0 billion, and $59.7 billion, respectively, indicating sustained growth momentum for the firm.
Bears say
Eli Lilly faces significant revenue risks due to the impending loss of exclusivity for several of its key products, which may lead to increased generic competition and a rapid decline in sales, particularly in the U.S. The company is also vulnerable to heightened pricing pressures and potential setbacks in its drug pipeline, which could further impede growth prospects and negatively impact future revenues and net income. Additionally, unforeseen quality and manufacturing issues could exacerbate these challenges, creating a compounded threat to the firm's financial stability.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares